Al-Izki, S, Kirkwood PA, Lemon RN, and Enríquez Denton M. (2008). Electrophysiological actions of the rubrospinal tract in the anaesthetised rat. Exp Neurol. 212:118-131.

Anderson, J.M., Hampton, D.W., Patani, R., Pryce, G., Crowther, R.A., Reynolds, R., Franklin, R.J.M., Giovannoni, G., Compston, D.A.S., and Baker, D. (2008). Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain 131: 1736-1748.

Cavanna, A.E., Martino, D., Orth, M., Giovannoni, G., Stern, J.S., Robertson, M.M., and Critchley, H.D. (2008). Neuropsychiatric-developmental model for the expression of tics, pervasive developmental disorder, and schizophreniform symptomatology associated with PANDAS. World J. Biol. Psychiatry (Epub ahead of print).

Cohen, B.A., Oger, J., Gagnon, A., and Giovannoni, G. (2008). The implications of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci. 275:7-17.

Croxford, J.L., Pryce, G., Jackson, S.J., Ledent, C., Giovannoni, G., Pertwee, R.G., Yamamura, T., and Baker, D. (2008). Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J Neuroimmunol 193, 120-129.

East, E., Gveric, D., Baker, D., Pryce, G., Lijnen, H.R., and Cuzner, M.L. (2008). Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation. Neuropathol Appl Neurobiol 34, 216-230.

Farrell, R., Kapoor, R., Leary, S., Rudge, P., Thompson, A.J., Miller, D.H., and Giovannoni, G. (2008). Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. Mult Scler 14, 214-218.

Farrell, R., Bendtzen, K., Bertolotto, A., Clark, B., Comabella, M., Deisenhammer, F., Fogdell-Hahn, A., Giovannoni, G., Hartung, H.P., Hemmer, B., Hillert, J., Kappos, L., Killestein, J., Lindberg, R., Montalban, X., Polman, C., and Sorensen, P.S. (2008). Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 36, 204-208; author reply 208-210.

Gani, R., Giovannoni, G., Bates, D., Kemball, B., Hughes, S., and Kerrigan, J. (2008). Cost-Effectiveness Analyses of Natalizumab (Tysabri (R)) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK. Pharmacoeconomics. 26(7):617-627, 2008.

Giovannoni, G. (2008). To test or not to test: NMO-IgG and optic neuritis.
 Neurology, Vol. 70, Issue 23, 2192-2193

Giovannoni, G., Barbarash, O., Casset-Semanaz, F., King, J., Metz, L., Pardo, G., Simsarian, J., Sørensen, P.S., and Stubinski, B. (2008). Safety and immunogenicity of a new formulation of interferon {beta}-1a (Rebif (R) New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Multiple Sclerosis (Epub ahead of print).

Guo JP, Bäckdahl L, Marta M, Mathsson L, Rönnelid J, Lorentzen JC. (2008). Profound and paradoxical impact on arthritis and autoimmunity of the rat antigen-presenting lectin-like receptor complex. Arthritis Rheum. 58:1343-53.

Hampton, D.W., Anderson, J., Pryce, G., Irvine, K.A., Giovannoni, G., Fawcett, J.W., Compston, A., Franklin, R.J.M., Baker, D., and Chandran, S. (2008). An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. Journal of Neuroimmunology  201: 200 – 211.

Hintzen, R.Q., and Giovannoni, G. (2008). CSF analysis in suspected MS: Do bands aid? Neurology 70, 1059-1060.

Kappos, L., Gold, R., Miller, D.H., Macmanus, D.G., Havrdova, E., Limmroth, V., Polman, C.H., Schmierer, K., Yousry, T.A., Yang, M., Eraksoy, M., Meluzinova, E., Rektor, I., Dawson, KT, Sandrock, A.W., O'Neill, G.N., and for the BG-12 Phase IIb Study Investigators (2008).  Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372:1463-1472.

Lam R, Farrell R, Aziz T, Gibbs E, Giovannoni G, Grossberg S, Oger J. (2008). .Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Methods 336:113-8.

Marta, M., Andersson, A., Isaksson, M., Kampe, O., and Lobell, A. (2008). Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur J Immunol 38, 565-575.

Martino, D., Draganski, B., Cavanna, A., Church, A., Defazio, G., Robertson, M.M., Frackowiak, R.S., Giovannoni, G., and Critchley, H.D. (2008). Anti-basal ganglia antibodies and Tourette's syndrome: A voxel-based morphometry and diffusion tensor imaging study in an adult population. J Neurol Neurosurg Psychiatry 79:820-822.

Pryce G, Jackson SJ, Baker D. (2008). Cannabinoids for the control of multiple sclerosis. In cannabinoids and the brain. Köfalvi A (Ed), Springer, Norwell, Massachusetts, USA.

Rejdak, K., Petzold, A., Stelmasiak, Z., and Giovannoni, G. (2008). Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult Scler 14, 59-66.

van de Warrenburg, B.P., Church, A.J., Martino, D., Candler, P.M., Bhatia, K.P., Giovannoni, G., and Quinn, N.P. (2008). Antineuronal antibodies in Parkinsons disease. Movement Disorders 23: 958-963.